The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population
To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene. The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investig...
Gespeichert in:
| Veröffentlicht in: | European urology 2005-10, Vol.48 (4), p.679-685 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 685 |
|---|---|
| container_issue | 4 |
| container_start_page | 679 |
| container_title | European urology |
| container_volume | 48 |
| creator | Giwercman, Yvonne L Abrahamsson, Per-Anders Giwercman, Aleksander Gadaleanu, Virgil Ahlgren, Göran |
| description | To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene.
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
The SRD5A2 high-activity allele variants A49T AT and V89L LL were more frequent in CaP-patients compared to general population, p=0.026 and p=0.05, respectively. CaP progression was, however, independent of SRD5A2 variants. In contrary, men with GGN |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68582458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68582458</sourcerecordid><originalsourceid>FETCH-LOGICAL-p544-69791ed9f06200b4ce98b35480b2a5796a95f473f1498be23693965dcf2173633</originalsourceid><addsrcrecordid>eNo1kL1OwzAUhTOAaCm8AvLEFsmJ7cQeq4qfSpVYItboxrlpjBzHxE5RX4WnJYiynDt8n66OzlWypozmaS6ZXCW3IXxQSplQ7CZZZQVlqiz5OvmueiQCrO8hnbCddYSAJJ49kv2ebLmqCLiWvEt1IL059inoaE4mnglYi9ZocoLJgIuBwIRkGJfQ4zCMjhhHBnTky8Se-GkMEeLCwGmcfhW_-O0fjUuHIzqcwBI_-tlCNKO7S647sAHvL3eTVM9P1e41Pby97HfbQ-oF52mhSpVhqzpa5JQ2XKOSDRNc0iYHUaoClOh4ybqMLwBzViimCtHqLs9KVjC2SR7_3i4dP2cMsR5M0GgtOBznUBdSyJwLuYgPF3FuBmxrP5kBpnP9Pyb7AbDMb_c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68582458</pqid></control><display><type>article</type><title>The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Giwercman, Yvonne L ; Abrahamsson, Per-Anders ; Giwercman, Aleksander ; Gadaleanu, Virgil ; Ahlgren, Göran</creator><creatorcontrib>Giwercman, Yvonne L ; Abrahamsson, Per-Anders ; Giwercman, Aleksander ; Gadaleanu, Virgil ; Ahlgren, Göran</creatorcontrib><description>To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene.
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
The SRD5A2 high-activity allele variants A49T AT and V89L LL were more frequent in CaP-patients compared to general population, p=0.026 and p=0.05, respectively. CaP progression was, however, independent of SRD5A2 variants. In contrary, men with GGN<23 had a higher risk of dying from the disease than their counterparts with longer repeats.
Men with CaP were more often genetically predisposed to a higher enzymatic activity in the turn over from T to DHT compared to the general population. In our population, androgen receptor genotype affected CaP outcome.</description><identifier>ISSN: 0302-2838</identifier><identifier>PMID: 16039774</identifier><language>eng</language><publisher>Switzerland</publisher><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - blood ; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics ; Aged ; Alanine ; Alleles ; Arginine ; Biomarkers, Tumor - blood ; Case-Control Studies ; Dihydrotestosterone - blood ; Disease Progression ; Follow-Up Studies ; Genetic Predisposition to Disease ; Genotype ; Glutamine ; Humans ; Leucine ; Luteinizing Hormone - blood ; Male ; Middle Aged ; Point Mutation ; Polymorphism, Genetic ; Prostatic Hyperplasia - blood ; Prostatic Hyperplasia - epidemiology ; Prostatic Hyperplasia - genetics ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - epidemiology ; Prostatic Neoplasms - genetics ; Receptors, Androgen - blood ; Receptors, Androgen - genetics ; Risk Factors ; Sex Hormone-Binding Globulin - metabolism ; Sweden - epidemiology ; Terminal Repeat Sequences ; Testosterone - blood ; Threonine ; Valine</subject><ispartof>European urology, 2005-10, Vol.48 (4), p.679-685</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16039774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giwercman, Yvonne L</creatorcontrib><creatorcontrib>Abrahamsson, Per-Anders</creatorcontrib><creatorcontrib>Giwercman, Aleksander</creatorcontrib><creatorcontrib>Gadaleanu, Virgil</creatorcontrib><creatorcontrib>Ahlgren, Göran</creatorcontrib><title>The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene.
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
The SRD5A2 high-activity allele variants A49T AT and V89L LL were more frequent in CaP-patients compared to general population, p=0.026 and p=0.05, respectively. CaP progression was, however, independent of SRD5A2 variants. In contrary, men with GGN<23 had a higher risk of dying from the disease than their counterparts with longer repeats.
Men with CaP were more often genetically predisposed to a higher enzymatic activity in the turn over from T to DHT compared to the general population. In our population, androgen receptor genotype affected CaP outcome.</description><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - blood</subject><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics</subject><subject>Aged</subject><subject>Alanine</subject><subject>Alleles</subject><subject>Arginine</subject><subject>Biomarkers, Tumor - blood</subject><subject>Case-Control Studies</subject><subject>Dihydrotestosterone - blood</subject><subject>Disease Progression</subject><subject>Follow-Up Studies</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Glutamine</subject><subject>Humans</subject><subject>Leucine</subject><subject>Luteinizing Hormone - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Point Mutation</subject><subject>Polymorphism, Genetic</subject><subject>Prostatic Hyperplasia - blood</subject><subject>Prostatic Hyperplasia - epidemiology</subject><subject>Prostatic Hyperplasia - genetics</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Receptors, Androgen - blood</subject><subject>Receptors, Androgen - genetics</subject><subject>Risk Factors</subject><subject>Sex Hormone-Binding Globulin - metabolism</subject><subject>Sweden - epidemiology</subject><subject>Terminal Repeat Sequences</subject><subject>Testosterone - blood</subject><subject>Threonine</subject><subject>Valine</subject><issn>0302-2838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kL1OwzAUhTOAaCm8AvLEFsmJ7cQeq4qfSpVYItboxrlpjBzHxE5RX4WnJYiynDt8n66OzlWypozmaS6ZXCW3IXxQSplQ7CZZZQVlqiz5OvmueiQCrO8hnbCddYSAJJ49kv2ebLmqCLiWvEt1IL059inoaE4mnglYi9ZocoLJgIuBwIRkGJfQ4zCMjhhHBnTky8Se-GkMEeLCwGmcfhW_-O0fjUuHIzqcwBI_-tlCNKO7S647sAHvL3eTVM9P1e41Pby97HfbQ-oF52mhSpVhqzpa5JQ2XKOSDRNc0iYHUaoClOh4ybqMLwBzViimCtHqLs9KVjC2SR7_3i4dP2cMsR5M0GgtOBznUBdSyJwLuYgPF3FuBmxrP5kBpnP9Pyb7AbDMb_c</recordid><startdate>200510</startdate><enddate>200510</enddate><creator>Giwercman, Yvonne L</creator><creator>Abrahamsson, Per-Anders</creator><creator>Giwercman, Aleksander</creator><creator>Gadaleanu, Virgil</creator><creator>Ahlgren, Göran</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200510</creationdate><title>The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population</title><author>Giwercman, Yvonne L ; Abrahamsson, Per-Anders ; Giwercman, Aleksander ; Gadaleanu, Virgil ; Ahlgren, Göran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p544-69791ed9f06200b4ce98b35480b2a5796a95f473f1498be23693965dcf2173633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - blood</topic><topic>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics</topic><topic>Aged</topic><topic>Alanine</topic><topic>Alleles</topic><topic>Arginine</topic><topic>Biomarkers, Tumor - blood</topic><topic>Case-Control Studies</topic><topic>Dihydrotestosterone - blood</topic><topic>Disease Progression</topic><topic>Follow-Up Studies</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Glutamine</topic><topic>Humans</topic><topic>Leucine</topic><topic>Luteinizing Hormone - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Point Mutation</topic><topic>Polymorphism, Genetic</topic><topic>Prostatic Hyperplasia - blood</topic><topic>Prostatic Hyperplasia - epidemiology</topic><topic>Prostatic Hyperplasia - genetics</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Receptors, Androgen - blood</topic><topic>Receptors, Androgen - genetics</topic><topic>Risk Factors</topic><topic>Sex Hormone-Binding Globulin - metabolism</topic><topic>Sweden - epidemiology</topic><topic>Terminal Repeat Sequences</topic><topic>Testosterone - blood</topic><topic>Threonine</topic><topic>Valine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giwercman, Yvonne L</creatorcontrib><creatorcontrib>Abrahamsson, Per-Anders</creatorcontrib><creatorcontrib>Giwercman, Aleksander</creatorcontrib><creatorcontrib>Gadaleanu, Virgil</creatorcontrib><creatorcontrib>Ahlgren, Göran</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giwercman, Yvonne L</au><au>Abrahamsson, Per-Anders</au><au>Giwercman, Aleksander</au><au>Gadaleanu, Virgil</au><au>Ahlgren, Göran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2005-10</date><risdate>2005</risdate><volume>48</volume><issue>4</issue><spage>679</spage><epage>685</epage><pages>679-685</pages><issn>0302-2838</issn><abstract>To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene.
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
The SRD5A2 high-activity allele variants A49T AT and V89L LL were more frequent in CaP-patients compared to general population, p=0.026 and p=0.05, respectively. CaP progression was, however, independent of SRD5A2 variants. In contrary, men with GGN<23 had a higher risk of dying from the disease than their counterparts with longer repeats.
Men with CaP were more often genetically predisposed to a higher enzymatic activity in the turn over from T to DHT compared to the general population. In our population, androgen receptor genotype affected CaP outcome.</abstract><cop>Switzerland</cop><pmid>16039774</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-2838 |
| ispartof | European urology, 2005-10, Vol.48 (4), p.679-685 |
| issn | 0302-2838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68582458 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - blood 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics Aged Alanine Alleles Arginine Biomarkers, Tumor - blood Case-Control Studies Dihydrotestosterone - blood Disease Progression Follow-Up Studies Genetic Predisposition to Disease Genotype Glutamine Humans Leucine Luteinizing Hormone - blood Male Middle Aged Point Mutation Polymorphism, Genetic Prostatic Hyperplasia - blood Prostatic Hyperplasia - epidemiology Prostatic Hyperplasia - genetics Prostatic Neoplasms - blood Prostatic Neoplasms - epidemiology Prostatic Neoplasms - genetics Receptors, Androgen - blood Receptors, Androgen - genetics Risk Factors Sex Hormone-Binding Globulin - metabolism Sweden - epidemiology Terminal Repeat Sequences Testosterone - blood Threonine Valine |
| title | The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T15%3A14%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%205alpha-reductase%20type%20II%20A49T%20and%20V89L%20high-activity%20allelic%20variants%20are%20more%20common%20in%20men%20with%20prostate%20cancer%20compared%20with%20the%20general%20population&rft.jtitle=European%20urology&rft.au=Giwercman,%20Yvonne%20L&rft.date=2005-10&rft.volume=48&rft.issue=4&rft.spage=679&rft.epage=685&rft.pages=679-685&rft.issn=0302-2838&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68582458%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68582458&rft_id=info:pmid/16039774&rfr_iscdi=true |